Walleye Capital’s GSK GSK Stock Holding History

Walleye Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.18M	Sell	60,700 -64,000	-51%	-$3.38M	0.01%	1135
2026 Q1	$6.88M	Sell	124,700 -206,000	-62%	-$11.2M	0.03%	603
2025 Q4	$16.2M	Buy	330,700 +254,100	+332%	+$11.9M	0.05%	388
2025 Q3	$3.31M	Buy	76,600 +1,600	+2%	+$62.5K	0.01%	1209
2025 Q2	$2.88M	Buy	75,000 +64,300	+601%	+$2.46M	0.01%	1243
2025 Q1	$415K	Sell	10,700 -11,200	-51%	-$410K	﹤0.01%	2706
2024 Q4	$741K	Sell	21,900 -104,300	-83%	-$3.75M	﹤0.01%	2647
2024 Q3	$5.16M	Buy	126,200 +18,400	+17%	+$753K	0.01%	1145
2024 Q2	$4.15M	Sell	107,800 -164,100	-60%	-$6.9M	0.01%	1432
2024 Q1	$11.7M	Buy	271,900 +154,300	+131%	+$6.36M	0.02%	751
2023 Q4	$4.36M	Buy	117,600 +13,100	+13%	+$470K	0.01%	1188
2023 Q3	$3.79M	Buy	104,500 +30,000	+40%	+$1.06M	0.01%	1241
2023 Q2	$2.66M	Buy	74,500 +31,200	+72%	+$1.12M	0.01%	1134
2023 Q1	$1.54M	Buy	+43,300	New	+$1.51M	0.02%	875
2022 Q4	–	Sell	-6,500	Closed	-$191K	–	3358
2022 Q3	$191K	Buy	+6,500	New	+$246K	﹤0.01%	2146

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Walleye Capital's GSK Position: Q2 2026 in Review

Walleye Capital increased its GSK (GSK) stake by 7.9% in Q2 2026, buying an estimated $1.55M and bringing the position to 402,472 shares worth $21.1M. The position accounts for 0.08% of the portfolio, ranked #237.

Walleye Capital first reported a position in GSK in Q3 2018 and has held it in 12 quarters since. 1,042 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Walleye Capital held 402,472 shares of GSK worth $21.1M as of Q2 2026.
Walleye Capital bought 29,376 GSK shares in Q2 2026, an estimated $1.55M.
GSK made up 0.08% of Walleye Capital's portfolio in Q2 2026, its #237 holding.
Walleye Capital first reported a position in GSK in Q3 2018 and has held it in 12 quarters since.
1,042 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.